CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Planned sale Director sold 3,485 shares at $19.15 ($66,729)
- SC 13D/A Stake Beneficial Ownership Report
- 4 Planned sale Director sold 3,237 shares at $19.08 ($61,758)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $18.60 ($223,146)
- D Other Notice of Sales of Unregistered Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at an average $18.25 ($59,302)
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at an average $17.56 ($210,661)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 13,278 shares at $19.16 ($254,462)
- 4 Planned sale Director sold 1,270 shares at $14.50 ($18,419)
- 144 Insider Sale of Securities
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Planned sale CHIEF OPERATING OFFICER sold 4,875 shares at $15.64 ($76,239)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $16.42 ($197,006)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $16.97 ($55,163)
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at an average $16.89 ($202,653)
Page 22 of 40 · 798 filings